Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia a

Blood

Volumn 122, Issue 11, 2013, Pages 1954-1962

  Eckhardt, Corien L ^a   Van Velzen, Alice S ^a   Peters, Marjolein ^a   Astermark, Jan ^b   Brons, Paul P ^c   Castaman, Giancarlo ^d   Cnossen, Marjon H ^e   Dors, Natasja ^f   Escuriola Ettingshausen, Carmen ^g   Hamulyak, Karly ^h   Hart, Daniel P ⁱ   Hay, Charles R M ^j   Haya, Saturnino ^k   Van Heerde, Waander L ^c   Hermans, Cedric ^l   Holmström, Margareta ^m   Jimenez Yuste, Victor ⁿ   Keenan, Russell D ^o   Klamroth, Robert ^p   Laros van Gorkom, Britta A P ^c   Leebeek, Frank W G ^e   Liesner, Ri ^q   Mäkipernaa, Anne ^r   Male, Christoph ^s   Mauser Bunschoten, Evelien ^t   Mazzucconi, Maria G ^u   McRae, Simon ^v   Meijer, Karina ^w   Mitchell, Michael ^x   Morfini, Massimo ^y   Nijziel, Marten ^z   Oldenburg, Johannes ^aa   Peerlinck, Kathelijne ^ab   Petrini, Pia ^m   Platokouki, Helena ^ac   Reitter Pfoertner, Sylvia E ^s   Santagostino, Elena ^ad   Schinco, Piercarla ^ae   Smiers, Frans J ^af   Siegmund, Berthold ^ag   Tagliaferri, Annarita ^ah   Yee, Thynn T ^ai   Kamphuisen, Pieter Willem ^a   Van Der Bom, Johanna G ^af,aj   Fijnvandraat, Karin ^a   more..

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d SAN BORTOLO HOSPITAL   (Italy)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f CATHARINA HOSPITAL   (Netherlands)

^g UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^h MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ ROYAL LONDON HOSPITAL   (United Kingdom)

^j MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^k HOSPITAL UNIVERSITARIO LA FE   (Spain)

^l CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^m KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

ⁿ HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^o ALDER HEY CHILDREN S HOSPITAL   (United Kingdom)

^p VIVANTES KLINIKUM IM FRIEDRICHSHAIN   (Germany)

^q GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^r UNIVERSITY OF HELSINKI AND HELSINKI UNIVERSITY HOSPITAL   (Finland)

^s MEDICAL UNIVERSITY OF VIENNA   (Austria)

^t UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^u SAPIENZA UNIVERSITY OF ROME   (Italy)

^v ROYAL ADELAIDE HOSPITAL   (Australia)

^w UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^x GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^y CAREGGI UNIVERSITY HOSPITAL   (Italy)

^z MÁXIMA MEDICAL CENTER   (Netherlands)

^aa UNIVERSITY HOSPITAL BONN   (Germany)

^ab UNIVERSITY OF LEUVEN   (Belgium)

^ac AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

^ad FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^ae MOLINETTE HOSPITAL   (Italy)

^af LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^ag Raphaels Klinik Munster GmbH   (Germany)

^ah UNIVERSITY HOSPITAL OF PARMA   (Italy)

^ai ROYAL FREE HOSPITAL   (United Kingdom)

^aj SANQUIN RESEARCH   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; NEUTRALIZING ANTIBODY;

ADULT; AGED; ALLOIMMUNITY; AMINO ACID SUBSTITUTION; ARTICLE; AUSTRALIA; BLEEDING TENDENCY; COHORT ANALYSIS; DISEASE SEVERITY; EUROPE; GENOTYPE; HEMOPHILIA A; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MULTICENTER STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ADOLESCENT; FOLLOW UP; GENETICS; IMMUNOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; RISK FACTOR; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIBODIES, NEUTRALIZING; FACTOR VIII; FOLLOW-UP STUDIES; GENOTYPE; HEMOPHILIA A; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MUTATION, MISSENSE; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84887363261     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-02-483263     Document Type: Article

References (31)

1. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia. 2003;9(4):418-435.
2. Fijnvandraat K, Cnossen MH, Leebeek FW, Peters M. Diagnosis and management of haemophilia. BMJ. 2012;344:e2707.
3. Di Minno MN, Di Minno G, Di Capua M, Cerbone AM, Coppola A. Cost of care of haemophilia with inhibitors. Haemophilia. 2010;16(1):e190-e201.
4. Hay CR, Ludlam CA, Colvin BT, et al UK Haemophilia Centre Directors Organisation. Factor VIII inhibitors in mild and moderateseverity haemophilia A. Thromb Haemost. 1998; 79(4):762-766.
5. Boekhorst J, Lari GR, D'Oiron R, et al. Factor VIII genotype and inhibitor development in patients with haemophilia A: highest risk in patients with splice site mutations. Haemophilia. 2008;14(4): 729-735.
6. Oldenburg J, El-Maarri O, Schwaab R. Inhibitor development in correlation to factor VIII genotypes. Haemophilia. 2002;8(Suppl 2):23-29.
7. Gouw SC, van den Berg HM, Oldenburg J, et al. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood. 2012;119(12): 2922-2934.
8. d'Oiron R, Pipe SW, Jacquemin M. Mild/moderate haemophilia A: new insights into molecular mechanisms and inhibitor development. Haemophilia. 2008;14(Suppl 3):138-146.
9. Kemball-Cook G. The Haemophilia A Mutation, Structure, Test and Resource Site. http://www. hadb.org.uk/. Accessed April 15, 2013.
10. Centers for Disease Control and Prevention. CHAMP: CDC Hemophilia A Mutation Project. http://www.cdc.gov/ncbddd/hemophilia/champs. html. Accessed April 15, 2013.
11. Vidal F, Farssac E, Altisent C, Puig L, Gallardo D. Rapid hemophilia A molecular diagnosis by a simple DNA sequencing procedure: identification of 14 novel mutations. Thromb Haemost. 2001; 85(4):580-583.
12. Genomic Disorders Research Centre. HGVS: Human Genome Variation Society. http://www.hgvs.org. Accessed February 5, 2013.
13. Kasper CK, Aledort L, Aronson D, et al. Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh. 1975;34(2):612.
14. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost. 1995;73(2):247-251.
15. Harrel FE. Missing Data: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York, NY: Springer; 2001.
16. Collins PW, Chalmers E, Hart DP, et al. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization. Br J Haematol. 2013;160(2):153-70.
17. Hay CR, Palmer B, Chalmers E, et al United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO). Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood. 2011;117(23): 6367-6370.
18. Schwaab R, Pavlova A, Albert T, Caspers M, Oldenburg J. Significance of F8 missense mutations with respect to inhibitor formation. Thromb Haemost. 2013;109(3):464-470.
19. Kempton CL, Soucie JM, Miller CH, et al. In nonsevere hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study. J Thromb Haemost. 2010;8(10):2224-2231.
20. Eckhardt CL, Menke LA, van Ommen CH, et al. Intensive peri-operative use of factor VIII and the Arg593 - →Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A. J Thromb Haemost. 2009;7(6):930-937.
21. Eckhardt CL, van der Bom JG, van der Naald M, Peters M, Kamphuisen PW, Fijnvandraat K. Surgery and inhibitor development in hemophilia A: a systematic review. J Thromb Haemost. 2011; 9(10):1948-1958.
22. Smith GD, Ebrahim S. Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol. 2004;33(1):30-42.
23. Strauss HS. The perpetuation of hemophilia by mutation. Pediatrics. 1967;39(2):186-193.
24. Astermark J, Oldenburg J, Carlson J, Pavlova A, Kavakli K, Berntorp E, Lefvert AK. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood. 2006;108(12):3739-3745.
25. Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK; MIBS Study Group. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood. 2006;107(8): 3167-3172.
26. Astermark J, Wang X, Oldenburg J, Berntorp E, Lefvert AK; MIBS Study Group. Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. J Thromb Haemost. 2007;5(2): 263-265.
27. Astermark J, Berntorp E, White GC, Kroner BL; MIBS Study Group. The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia. 2001;7(3): 267-272.
28. Sheehan NA, Didelez V, Burton PR, Tobin MD. Mendelian randomisation and causal inference in observational epidemiology. PLoS Med. 2008; 5(8):e177.
29. Meijer P, Verbruggen B. The between-laboratory variation of factor VIII inhibitor testing: the experience of the external quality assessment program of the ECAT foundation. Semin Thromb Hemost. 2009;35(8):786-793.
30. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first twenty years. Haemophilia. 2000;6(Suppl 1):60-67.
31. Castaman G, Mancuso ME, Giacomelli SH, Tosetto A, Santagostino E, Mannucci PM, Rodeghiero F. Molecular and phenotypic determinants of the response to desmopressin in adult patients with mild hemophilia A. J Thromb Haemost. 2009;7(11):1824-1831.